CIGNA Announces Appearance at the 2011 J.P. Morgan Healthcare Conference

PHILADELPHIA--(BUSINESS WIRE)-- CIGNA Corporation (NYSE: CI) announced today that David Cordani, President and CEO, CIGNA Corp. will be presenting at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011 in San Francisco, CA.

CIGNA's presentation is expected to begin at approximately 8:30 a.m. Pacific Standard Time. Investors, analysts, and the general public are invited to listen to the presentation free over the Internet via webcast by visiting http://www.cigna.com and clicking on Investors, then the Event Calendar link.

To listen to this presentation live on the Internet, visit http://www.cigna.com at least 15 minutes prior to the presentation (to download and install any necessary audio software).

CIGNA Corporation is a global health service company dedicated to helping people improve their health, well-being and sense of security. CIGNA's operating subsidiaries provide health and related benefits to customers throughout the United States and around the world, including health care products and services, life, accident and disability insurance and expatriate benefits. As of December 31, 2009, CIGNA Corporation and its subsidiaries had shareholders' equity of $5.4 billion. Full-year 2009 revenues totaled $18.4 billion. To learn more about CIGNA, visit http://www.cigna.com.



CONTACT:

CIGNA Corporation
Ted Detrick, Investor Relations, +1-215-761-1414

KEYWORDS:   United States  North America  California  Pennsylvania

INDUSTRY KEYWORDS:   Health  Professional Services  Insurance  Managed Care

MEDIA:

Logo
 Logo

Report

Driving Engagement in an Evolving Healthcare Ecosystem

Deep-dive into evolving consumer expectations in healthcare today and how leading providers are shaping their infrastructure to connect with patients through virtual care.

Suggested Articles

The Supreme Court will decide whether to reinstall Arkansas and New Hampshire's controversial Medicaid work requirements program.

The latter half of 2020 has seen the 340B program in turmoil.

CMS' most-favored-nation drug payment model isn't likely to lower most Medicare beneficiaries' out-of-pocket costs, an Avalere analysis found.